ArticleOncoimmunology2022

Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells.

Karthikeyan Subbarayan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.